Avadel Pharmaceuticals plc
Avadel Pharmaceuticals plc (AVDL) Stock Overview
Explore Avadel Pharmaceuticals plc’s financial performance, market position, analyst ratings, and future outlook.
Key Financials
Key Financials
Market Cap
2.1B
P/E Ratio
-7558.74
EPS (TTM)
$-0.02
ROE
-0.00%
AVDL Stock Analysis & Investment Overview
Our comprehensive AI-powered analysis of Avadel Pharmaceuticals plc (AVDL) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B+, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.
The current technical analysis reveals key indicators including an RSI of 56.78, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $18.59.
Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -7558.74 and a market capitalization of 2.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.